HeimGRFS • NASDAQ
add
Grifols SA - ADR ADR Class B
Við síðustu lokun
8,59 $
Dagbil
8,44 $ - 8,63 $
Árabil
6,19 $ - 11,14 $
Markaðsvirði
7,48 ma. USD
Meðalmagn
592,91 þ.
V/H-hlutf.
12,56
A/V-hlutfall
2,04%
Fjármál
Rekstrarreikningur
Tekjur
Nettótekjur
| (EUR) | des. 2025info | Breyting á/á |
|---|---|---|
Tekjur | 1,98 ma. | 0,32% |
Rekstrarkostnaður | 353,11 m. | 0,09% |
Nettótekjur | 98,25 m. | 42,29% |
Hagnaðarhlutfall | 4,96 | 41,71% |
Hagnaður á hvern hlut | — | — |
EBITDA | 422,88 m. | -14,62% |
Virkt skatthlutfall | -13,21% | — |
Efnahagsreikningur
Heildareignir
Heildarskuldir
| (EUR) | des. 2025info | Breyting á/á |
|---|---|---|
Reiðufé og skammtímafjárfestingar | 849,00 m. | -15,44% |
Heildareignir | 19,71 ma. | -7,91% |
Heildarskuldir | 12,11 ma. | -5,39% |
Eigið fé alls | 7,60 ma. | — |
Útistandandi hlutabréf | 680,58 m. | — |
Eiginfjárgengi | 1,11 | — |
Arðsemi eigna | 4,39% | — |
Ávöxtun eigin fjár | 5,04% | — |
Peningaflæði
Breyting á handbæru fé
| (EUR) | des. 2025info | Breyting á/á |
|---|---|---|
Nettótekjur | 98,25 m. | 42,29% |
Handbært fé frá rekstri | 430,86 m. | -16,25% |
Reiðufé frá fjárfestingum | -151,32 m. | 15,45% |
Reiðufé frá fjármögnun | -75,18 m. | -173,90% |
Breyting á handbæru fé | 203,82 m. | -39,27% |
Frjálst peningaflæði | 349,39 m. | 243,02% |
Um
Grifols, S.A. is a global healthcare company and leading producer of plasma-derived medicines founded in Barcelona, Catalonia, Spain, in 1909. With a workforce of over 23,800 employees, Grifols serves more than 110 countries and regions and maintains a direct presence in over than 30.
Principally a producer of blood plasma–based products and other biopharmaceuticals, the company also operates in transfusion medicine, supplying devices, instruments and reagents for clinical testing laboratories, as well as clinical diagnostic technologies. Furthermore, it provides biological supplies for life-science research, clinical trials and the manufacturing of pharmaceutical and diagnostic products. It has a portfolio on four therapeutic areas: immunology, infectious diseases, pulmonology and critical care. Wikipedia
Framkvæmdastjóri
Stofnsett
18. nóv. 1940
Vefsvæði
Starfsfólk
25.258
